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Senescence is a tumour suppressor mechanism which is cell-intrinsically activated in the
context of cellular stress. Senescence can further be propagated to neighbouring cells, a
process called secondary senescence induction. Secondary senescence was initially
shown as a paracrine response to the secretion of cytokines from primary senescent
cells. More recently, juxtacrine Notch signalling has been implicated in mediating second-
ary senescence induction. Primary and secondary senescent induction results in distinct
transcriptional outcomes. In addition, cell type and the stimulus in which senescence is
induced can lead to variations in the phenotype of the senescence response. It is unclear
whether heterogeneous senescent end-points are associated with distinct cellular func-
tion in situ, presenting functional heterogeneity. Thus, understanding senescence
heterogeneity could prove to be important when devising ways of targeting senescent
cells by senolytics, senostatics or senogenics. In this review, we discuss a role for func-
tional heterogeneity in senescence in tissue- and cell-type specific manners, highlighting
potential differences in senescence outcomes of primary and secondary senescence.
Introduction
In 1961, Hayflick and Moorhead [1] discovered, albeit in a rather serendipitous manner, that their cell
cultures faced proliferative exhaustion after an extended period of time. They suspected that the finite
proliferative capacity they observed in cell culture might limit the regenerative capacity of an ageing
organism and they, therefore, called the phenomenon cellular senescence. Years later, it was shown
that cellular senescence could also be induced in a more acute way, as shown by ectopic activation of
oncogenes such as oncogenic H-Ras (proto-oncogene mutated RASG12V) [2]. Ras-induced senes-
cence requires the activation of the Rb transcriptional co-repressor 1 (RB1) and tumour protein 53
(TP53) pathways and has emerged as a stable exit from the cell cycle and an important cell-intrinsic
tumour suppressor mechanism [3]. A growing body of evidence has since strengthened Hayflick’s sug-
gestion of a pathophysiological role in the loss of function and regenerative abilities in tissues and
organs as senescent cells build up over time [4,5]. The clearance of senescent cells leads to improved
health outcomes and an extension of healthy lifespan [6]. The accumulation of senescent cells has
thus served as a valuable concept to partially explain part of the complex process of ageing and the
manifestation of its associated pathologies [7]. In addition to being a barrier to tumourigenesis, senes-
cence has been associated with other physiological processes such as embryonic development [8,9]
and wound healing [10,11].
Besides proliferation-related telomere erosion and oncogenic insults, senescence is triggered by various
intrinsic and extrinsic factors, such as DNA damage [12], accumulation of reactive oxygen species
(ROS) [13], mitogen exposure [14], hypoxia [15], impaired ribosomal biogenesis [16] and mitochon-
drial dysfunction [17]. Post insult, cells exit the cell cycle by activation of TP53-mediated cyclin-
dependent kinase inhibitor 1A (CDKN1A or p21) and/or RB1-mediated negative cell-cycle regulation
via p15(INK4B) and p16(INK4A), with the involvement of DNA damage response (DDR) pathways
[12]. Fully senescent cells show distinct morphological features; cells often become flat and large, stain
positive for senescence-associated β galactosidase (SA-β Gal), whilst nuclear changes occur with the
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loss of Lamin B1 and chromatin remodelling towards heterochromatic foci, named senescence-associated het-
erochromatin foci (SAHF) [18–20]. Intrinsic nucleic acid sensing has been implicated in the senescence
response, where DNA shed from nuclei, forming cytoplasmic chromatin fragments (CCFs), is degraded in the
cytosol [21]. These CCFs are then sensed by the cytosolic DNA-sensing cGAS-STING pathway, resulting in the
activation of the senescence-associated secretory phenotype (SASP) [22–25]. Cytosolic nucleic acids might not
be the only way to involve innate immune pathways in the senescence response. A recent study shows the
involvement of Toll-like receptor 2 (TLR2) via the TP53, p16 and p15 pathways, thereby inducing cell cycle
arrest and induction of acute-phase serum amyloids, which are part of damage-associated molecular patterns
(DAMP). DAMPs in turn signal through pattern recognition receptors of the innate immune system such as
TLR2, thereby controlling the SASP and reinforcing cell cycle arrest during senescence [26].
SASP is one of the most dynamic and complex senescence features. Senescent cells are interacting with
themselves and their surrounding microenvironment via the SASP. SASP is characterised as a complex secre-
tome of inflammatory cytokines, chemokines, collagens, metalloproteinases (MMPs) such as interleukin 1
alpha (IL-α) and interleukin 6 (IL-6), together with tumour necrosis factor-alpha (TNF-α), vascular endothelial
growth factor (VEGF), insulin-like growth factor (IGF-1), chemokine CXC motif ligands 1 and 2 (CXCL1,
CXCL2) and interleukin 8 (IL-8), chemokine CC motif ligand 2 (CCL2) and transforming growth factor-beta
(TGF-β) [10,23,24]. Autocrine amplification of senescence occurs via binding of IL-6 to the IL-6 receptor and
through chemokines belonging to the CXC family such as IL-8, which bind to the CXCR2 receptor [27].
SASP is capable of inducing senescence in neighbouring cells exposed to the secretome, this is known as
paracrine secondary senescence, in contrast to primary senescence established from direct insults to the cell
[28,29]. It is thought that this is a mechanism with the purpose of increasing immune cell infiltration and
clearance of senescent cells to prevent the development of a pre-neoplastic niche. Failure to clear senescent cells
causes systemic inflammation and creates a pro-neoplastic and pro-ageing milieu [30]. Hence, the effect of
SASP is thought to be a double-edged sword.
In recent years, it has become clear that the senescence phenotype is variable depending on the affected cell
type, physiological location, the initial causal insult and the molecular pathways being favoured within the cells
[31] (Figure 1A). Similarly, SASP composition differs greatly depending on the original insult and cell type, but
not all senescent cells produce SASP [32]. This heterogeneity could resemble a scenario with functional diversi-
fication between primary senescence in a tissue-specific manner and between primary and secondary senes-
cence within the same organ. The concept of primary and secondary senescence being transcriptionally distinct
end-points has provided the biological imperative to investigate the mechanisms that govern such heterogeneity
[33]. The direction of future research on the development of senolytic therapies should, therefore, be guided by
the pursuit and understanding of this heterogeneity.
Senescence heterogeneity dependent on cell type and
stimulus
Heterogeneity in senescence outcomes in terms of, for example, SASP composition, stability and speed of
induction of the phenotype and SAHF formation have been widely described and can be attributed, in part, to
the cell type chosen and the senescence inducing agent. Within the scope of this review, we can only illustrate
a few examples of this heterogeneity.
Primary senescence heterogeneity
Human diploid fibroblasts (HDFs) such as IMR90, WI-38 (both embryonic lung fibroblasts) or BJ cells (from
foreskin) are standard models in the study of senescence [2,34]. Yet, in IMR90 and WI-38 cells, SAHF forma-
tion is more pronounced when given the same stimulus compared with BJ cells [18]. This might be dependent
on the levels of p16 pathway activation as senescence in BJ cells typically results in lower levels of p16, with
knockdown of RB/p16 abolishing SAHF formation in HDFs [18,35]. It might also depend on the oncogene of
choice (Figure 1B). For example, RASG12V-mediated senescence in HDFs leads to robust SAHF formation and
an increase in cell and nuclear size [18]. cRAF activation in the same HDFs leads to an even higher SAHF for-
mation, but no increase in cell size [36]. In contrast, weaker cell cycle arrest in the absence of SAHF and SASP
was observed upon activation of the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/KT
serine/threonine kinase (PI3K3CA/AKT) axis downstream of RAS in HDFs [37], pointing to differences in
cellular outcomes where parts of the same pathway might be activated to a different degree.
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In terms of SASP compositions, ectopic overexpression of Notch Receptor 1 (NOTCH1) in IMR90s led to a
highly specific primary senescence-dependent secretome, composed of collagens and TGF-β and a suppression
of the RASV12G-driven secretome, normally consisting of IL6/8, CCL2/3 and MMP1/3 [38] (Figure 1C).
Moreover, impaired ribosomal biogenesis induced senescence leads to a similarly restricted but yet distinct
SASP, characterised by TGF-β [16].
Secondary senescence heterogeneity
In HDFs, secondary senescence induction was originally thought to be solely explained by paracrine signalling
[29]. However, when we analysed single-cell RNA-sequencing data for primary RASV12G-mediated and sec-
ondary senescence in IMR90 fibroblasts, we identified a composite SASP signature, partially driven by paracrine
factors and partially driven by NOTCH [33]. This composite secondary senescence transcriptome led to a
subdued cytokine response via altered SASP elements previously reported for Notch-mediated primary senes-
cence [38] and a marked increase in fibrillar collagen production (Figure 1A,C,D). These alterations could indi-
cate fundamental functional differences between primary and secondary senescence in fibroblasts, leading to
Figure 1. Examples of cellular senescence heterogeneity.
(A) Senescence is a cell-type specific response. Fibroblasts and pancreatic beta-cells respond by up/down-regulating cell-type specific transcripts
and proteins. (B) Senescence response varies by inducing oncogene. Although part of the same pathway, RAS and RAF-induced senescence show
marked differences in fibroblasts. RAS-induced cells grow in size and form vacuoles. RAF-induced cells show a very high percentage of SAHF
positive cells. (C) Cell-to-cell variability in oncogene-induced senescence. We have recently shown that RAS induction can lead to a variety of
transcriptional end-points. We find an additional, secondary senescent end-point characterised by Notch signaling [30]. (D) A composite phenotype
results in secondary senescence. Secondary senescence induction can be mediated by primary senescent cells through SASP and Notch.
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context-dependent diverse senescence outcomes and functions. In this context, primary senescence might
confer a tumour suppressor activity, where a loss of normal function, namely collagen production, occurs.
Secondary senescent cells might, in turn, restore normal fibroblast function in an organ by secreting collagens
de novo in addition to senescence activation.
More recently, many studies reported the importance of membrane-bound extracellular vesicles such as exosomes
and small extracellular vesicles for senescent cell communication and the enforcement of the senescence phenotype.
These vesicles facilitate cellular protein transfer to mediate immune surveillance and communication with surround-
ing cells [39,40]. They can induce paracrine, secondary senescence and are part of the SASP. However, there is also
evidence that senescence-associated extracellular vesicles can be pro-tumourigenic, conferring pro-proliferative prop-
erties onto some types of cancer cells [41], again illustrating the context dependency of senescence features.
Overall, the huge variety of different secretomes produced by different senescence states and stimuli is likely
to create thus far unexplored heterogeneity in a cell type and tissue-specific manner, probably leading to dis-
tinct functions and clearance mechanisms. The benefits (clearance, tumour suppression, functional restoration)
and detrimental effects (pro-tumourigenic, pro-ageing) of the different SASP components in this context are
yet to be determined.
Senescence heterogeneity in tissue and disease context
Senescence in the skin
Human naevi are a widely used in vivo senescence model. Senescence heterogeneity in melanocytes is partially
oncogene dependent. For example, ectopic activation of RASG12V or b-Raf proto-oncogene-mutated V600E
(BRAFV600E) in human melanocytes results in oncogene-induced senescence with many shared phenotypes;
however, only RASG12V activation leads to an increase in cell size and vacuolization, whereas BRAFV600E activa-
tion leads to a significant increase in SAHF positive cells [42]. Ageing of the skin introduces heterogeneity in naevi
with different phenotypic changes in primary versus secondary skin senescence. p16 positive, senescent melano-
cytes accumulate dysfunctional telomeres during ageing [43]. However, neighbouring epidermal cells do not
up-regulate p16, but instead display telomere dysfunction and DNA damage, indicating secondary senescence
mediation in human naevi from melanocytes to epidermal cells [43]. Secondary senescence induction in the skin
might contribute to decreased epidermal regeneration and creates a heterogeneous environment in the ageing skin.
Senescence in the kidney
Studies to elucidate the function and consequences of a senescent population present in the kidney have also
illustrated context dependency in the effect of senescent cells [44], with tubular epithelial cells being most often
associated with renal senescence [45]. In kidneys, senescence contributes to fibrosis and tubular atrophy when
chronically present in aged tissues [46–48]. Moreover, in glomerular disease, the accumulation of p16-positive
cells probably leads to impaired repair and subsequent renal dysfunction [45]. In contrast, in autosomal domin-
ant polycystic kidney disease (ADPKD), where CDKN1A levels are typically low, there is some evidence sug-
gesting that roscovitine-mediated restoration of senescence, as measured by increased SA-β Gal and CDKN1A
expression, is beneficial and halts cystic progression [49]. These studies further highlight the complexity of
senescence in a tissue context, where senescence outcomes might be specific to disease type.
Senescence in the pancreas
During ageing, the senescence effector p16 is expressed in pancreatic β islet cells, limiting cell proliferation and
possibly regenerative capacity [50]. Senescent pancreatic β islet cells feature other typical senescence character-
istics, such as enlarged cell size and SA-β Gal production [51]. Interestingly, p16 expression in senescent pan-
creatic β islet cells increased glucose uptake and glucose stimulated insulin secretion when exposed to high
glucose concentrations, conferring a beneficial effect during ageing [51] (Figure 1A). In young mice and
human tissue context, a marked heterogeneity of β islet cells in terms of insulin secretion exists, which persists
during ageing, albeit to a lesser degree [52]. However, the levels of p16 and the expression of ageing-associated
cell surface proteins, such as insulin growth factor 1 receptor (IGF1R), vary greatly in aged β islet cells within
an individual, further suggesting functional heterogeneity in the pancreas during ageing [52], which again,
might be dependent on the degree of pathway regulation within a cell.
In contrast to the above described increased insulin secretion during ageing, another study showed that type 2
diabetes insulin resistance leads to increased proliferation of β islet cells and subsequent senescence. Here, as a
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consequence, the insulin release from senescent β islet cells decreases, thereby contributing to the pathogenesis of
type 2 diabetes [53]. In addition, in type 1 diabetes, elimination of a subset of senescent β islet cells was sufficient
for disease prevention [54]. Clearly, in diabetes, islet cell senescence contributes to disease pathogenesis and
might be a therapeutic target, whereas in an ageing context, islet cell senescence might be partially beneficial.
Wound healing and fibrosis in tissue context
Senescence-mediated wound healing and fibrosis has been reported in several tissues, with beneficial and detri-
mental aspects of senescence.
Beneficial aspects of senescence-mediated fibrosis were initially reported in the context of acute liver damage
where activated stellate cells underwent senescence [55]. These senescent hepatic stellate cells displayed down-
regulation of genes encoding extracellular matrix components with simultaneous up-regulation of extracellular
matrix degrading enzymes. Moreover, genes known to stimulate immune surveillance for senescent cell clear-
ance were also up-regulated [55]. This led to controlled, temporary fibrosis during acute liver damage, followed
by clearance of senescent cells. However, chronic liver damage was associated with proliferating, activated
stellate cells and extensive deposition of extracellular matrix proteins, eventually leading to cirrhosis and liver
failure [55]. In addition, studies in idiopathic pulmonary fibrosis highlighted the detrimental effects of pulmon-
ary senescence, partially by secretion of pro-fibrotic lipids, such as leukotrienes [56,57]. The context, but also
the kinetics in which cell senescence occurs are, therefore, clearly important factors to determine beneficial and
detrimental effects and should be considered more widely when targeting senescent cells.
The importance of kinetics is nicely demonstrated during wound healing, where skin senescence plays a role in
fibroblast-mediated collagen deposition and wound closure in young mice. This beneficial effect of senescence is
part of an integral interplay between senescent endothelial cells and fibroblasts, with transient up-regulation of
p16, CDKN1A and SA-β Gal in both cell types [11]. Senescent fibroblasts produce VEGF, platelet-derived growth
factor-AA (PDGF-AA) and SASP, thereby promoting tissue repair. VEGF, in turn, stimulates endothelial prolifer-
ation and revascularisation, allowing the transport of fibrinogens and coagulation factors to the wound [11]. The
elimination of senescent cells from wounds in mouse models decreased the time to wound closure. A study by Jun
and Lau [58] elucidated the mechanism in which extensive fibrosis during wound closure is curbed. They identified
the matricellular protein cellular communication network factor 1 (CCN1) as an important factor to induce fibro-
blast senescence and subsequent expression of senescence-associated anti-fibrotic genes [58]. Binding of CCN1 to
integrin α6β1 induced an ROS-dependent DDR, activating the TP53 and the p16/RB pathways, thereby limiting
fibrosis in cutaneous wounds. Furthermore, in 2015, a study by Shi et al. [59] reported a requirement for wingless
type (Wnt) and NOTCH pathway activation for timely wound closure. The involvement of NOTCH signalling
may implicate juxtacrine secondary senescence in the skin. In another study, transient exposure of keratinocytes to
SASP led to the up-regulation of stemness markers and increased regenerative skin capacity in vivo, suggesting a
beneficial effect of senescence mediators. However, prolonged exposure to SASP caused senescent cell cycle arrest
and reduced regenerative capacity [60], again illustrating kinetic-dependent heterogeneity in the outcome.
In conclusion, wound healing and age-related skin senescence highlight the differences in senescence
outcomes within the same tissue, with one senescence aspect — wound healing — being a desired outcome
and another one — reduced epidermal regeneration — conferring a potentially pro-ageing effect. The timing of
senescence might also lead to heterogeneity, where senescence-mediated stemness is promoted transiently, but
regenerative capacity decreased by persistent senescence. In addition, studies in liver highlight the importance
of the context and duration in which senescence occurs, with acute liver damage harvesting beneficial aspects
of senescence which turn detrimental in the context of chronic damage. Overall, senescence might be initially
beneficial in tissue context if it is properly controlled and senescent cells are cleared. However, where senes-
cence persists over time, negative effects promoting disease and ageing take over.
Functional senescence heterogeneity and response to
senescence therapy
Pro-senescence therapy
Senescence was originally described as a tumour suppressor pathway [2,3]. Therefore, in the context of anticancer
therapies, senescence induction is one way to influence tumour progression. Senescence can be induced by drugs,
such as Palbociclib, which engages with multiple senescence pathways. Palbociclib activates RB1 to induce cell
cycle arrest and it up-regulates the proteasome, causing cellular stress due to increased proteolysis [61,62].
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One of the main tumour suppressor pathways is the TP53 pathway. Therefore, targeting TP53 directly or
indirectly to reactivate the pathway is conceptually another anticancer intervention. In this context, TP53 res-
toration in malignant liver cancer led to senescence induction and tumour clearance in the mouse [63].
Restoration of TP53 in pre-neoplastic, proliferating pineal lesions also induced cellular senescence in mice [63].
However, TP53 restoration in invasive pineal tumours did not induce senescence, illustrating that cancer stage,
tissue type and timing of senescence induction are important and can lead to heterogeneous outcomes.
Anti-senescence therapy
Senolytics are drugs that selectively eliminate senescent cells, often by targeting pro-survival pathways that
increase resistance to apoptosis in senescent cells [64]. Several pro-survival networks have been identified relat-
ing to the PI3K/AKT and TP53 pathways and the BCL2 apoptosis regulator (BCL-2) family, varying with tissue
and senescence inducing mechanism [64]. Many current senolytics act in a cell type or inducer specific manner.
For example, Fisetin selectively eliminates senescent cells in umbilical vein endothelial cells (HUVECs), but not
in human lung fibroblasts (IMR90s) or preadipocytes. On the other hand, A1331852 and A1155463 are
senolytics effective in HUVECs and IMR90 cells, but not preadipocytes [65]. One of the most commonly
studied senolytics targeting PI3K/AKT upstream of NF-κB, Dasatinib, eliminates human adipocyte progenitors,
with a lesser effect on HUVECs [66]. In contrast, Querceptin, a potent antioxidant and metal ion chelator, has
little effect on preadipocytes, but induces apoptosis in senescent HUVECs compared with growing cells. Finally,
Navitoclax has been widely used in in vivo mouse models, effectively eliminating senescent cells in a variety of
tissues. However, Navitoclax is ill tolerated and was initially suggested as a broad-spectrum senolytic, with lethal
effects in HUVECs and IMR90 cells, but little effect on senescent preadipocytes [66].
Targeting the SASP through direct or indirect modulation of the NF-κB pathway has yielded some success
in a wide variety of model systems [65,66]. For example, glucocorticoids, a group of steroid hormones including
cortisol and corticosterone, have anti-inflammatory effects via down-regulation of NF-κB transcriptional activ-
ity [66]. Metformin is known to regulate glucose metabolism, but can also prevent NF-κB translocation to the
nucleus, thereby reducing the SASP. Moreover, mTor inhibitors, such as rapamycin, interfere with the IL-1α/
NF-κB axis, leading to reduced secretion of IL-6/8 [66]. Since IL-6/8 are important components of the SASP,
these might act on a wide variety of senescent cells.
In summary, more specific senescence therapies should aim to eliminate the detrimental effects of specific
senescence populations whilst not impacting on potential beneficial aspects of senescence. Therefore, careful
understanding of the different outcomes of senescence with regards to the whole organism, and not just select-
ive tissues, is necessary to enhance healthy life span, whilst promoting continued tissue repair and tumour sup-
pression. A broad range of tissue-specific senescence markers need to be assessed during senescence therapy to
gain a more complete picture.
Perspectives
• Senescence is a highly heterogeneous and complex cellular phenotype, with different effects
depending on tissue/cell of origin and senescence inducer. The interplay between primary and
secondary senescence and how they differ in contributing to age-related disease and cancer
outcomes are poorly understood. It is important to study the features of a heterogeneous
senescent cell population with the aim to enhance beneficial aspects of senescence (tumour
suppression, increase glucose production, wound healing) with simultaneous down-regulation
of damaging senescence aspects (inflammatory cytokine release, decreased regeneration).
• Senolytics are drugs that selectively eliminate senescent cells, targeting pro-survival pathways
that increase resistance to apoptosis in senescent cells. Pro-survival networks often vary with
tissue and senescence inducing mechanism, with current senolytics often acting in a cell type
or senescence inducer specific manner [64]. Senostatics, such as antioxidants, suppress
paracrine senescence signalling without killing the senescent cells and might be useful in
some contexts [67].
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).6
Biochemical Society Transactions (2020)
https://doi.org/10.1042/BST20190109
D
ow
nloaded from
 https://portlandpress.com
/biochem
soctrans/article-pdf/doi/10.1042/BST20190109/877913/bst-2019-0109c.pdf by U
K user on 11 M
ay 2020
• Characterising heterogeneity in senescent cell populations creates the basis for effective
senotherapy development. Therefore, the extent, interplay and consequences of primary and
secondary senescence and functional senescence heterogeneity need to be urgently addressed.
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